This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
GLP-1 agonists reduce body weight by 15-25% over about one year, but most patients regain weight after stopping. The review discusses strategies for safe discontinuation while maintaining weight loss.
Why it matters
Weight regain after stopping GLP-1 drugs is one of the biggest challenges in obesity treatment. Finding ways to taper off these medications without losing progress is critical for long-term success.
The numbers in context
40% of adults worldwide are overweight, 13% are obese. GLP-1 drugs reduce body weight by 15-25% after about 1 year. Boxed warning for medullary thyroid carcinoma and MEN2 history.
How the study worked
Narrative review of GLP-1 agonist mechanisms, efficacy, adverse effects, and discontinuation strategies for obesity treatment.
Who was studied
Adults with obesity using GLP-1 agonists for weight loss
What this study cannot tell us
Review article without original data. No proven discontinuation protocols exist. Long-term data on weight maintenance after stopping are limited. Newer agents have very short track records.
Read the original research
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss.
Biomolecules, 15(3)
Citation
Reiss, Allison B; Gulkarov, Shelly; Lau, Raymond; Klek, Stanislaw P; Srivastava, Ankita; Renna, Heather A; De Leon, Joshua. (2025). Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss.. Biomolecules, 15(3). https://doi.org/10.3390/biom15030408